The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man
Rationale A quantitative technique was used to compare the pharmacological potency in healthy volunteers of angiotensin II receptor antagonists (AIIA): candesartan cilexetil, losartan, irbesartan, valsartan, and telmisartan. Methods In a randomised, double-blind, parallel-group (4x12 subjects) study...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2000-12-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | https://doi.org/10.3317/jraas.2000.063 |
| _version_ | 1797285448698036224 |
|---|---|
| author | Gustav G Belz Kerstin Breithaupt-Grögler Raunhild Butzer Winfried Fuchs Christian Hausdorf Christian Mang |
| author_facet | Gustav G Belz Kerstin Breithaupt-Grögler Raunhild Butzer Winfried Fuchs Christian Hausdorf Christian Mang |
| author_sort | Gustav G Belz |
| collection | DOAJ |
| description | Rationale A quantitative technique was used to compare the pharmacological potency in healthy volunteers of angiotensin II receptor antagonists (AIIA): candesartan cilexetil, losartan, irbesartan, valsartan, and telmisartan. Methods In a randomised, double-blind, parallel-group (4x12 subjects) study, single oral doses of candesartan cilexetil 4, 8 and 16 mg, losartan potassium 25, 50 and 100 mg, valsartan 40, 80 and 160 mg, and irbesartan 75, 150 and 300 mg were administered on three consecutive days. Telmisartan 20, 40 and 80 mg was similarly evaluated in 12 volunteers in an open amendment. Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated. Apparent K i -doses, i.e. doses (in mg) required to induce a two-fold shift in Ang II dose-response curves (equivalent to approx. 50% blockade of receptors) were determined, using Schild regression analysis. Results All treatments dose-dependently attenuated increases in diastolic BP induced by infusion of exogenous Ang II. Candesartan cilexetil appeared to have a more pronounced increase in effect following cumulative dosing. At 24 hours, apparent K i -doses were: candesartan cilexetil 6 mg, irbesartan 123 mg, valsartan 93.5 mg, and telmisartan 54 mg. It was not possible to determine an apparent K i -dose for losartan at 24 hours. Conclusion Consistent with results from experimental pharmacology, candesartan cilexetil displayed the highest pharmacological potency (i.e. antagonistic activity per mg substance) of the AIIAs tested. Apparent K i -doses at 24 hours were within the dose range recommended for clinical use in patients with hypertension. |
| first_indexed | 2024-03-07T18:03:18Z |
| format | Article |
| id | doaj.art-1fa6232b0cd44747a9b9d01d8bc94c46 |
| institution | Directory Open Access Journal |
| issn | 1470-3203 |
| language | English |
| last_indexed | 2024-03-07T18:03:18Z |
| publishDate | 2000-12-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Journal of the Renin-Angiotensin-Aldosterone System |
| spelling | doaj.art-1fa6232b0cd44747a9b9d01d8bc94c462024-03-02T10:10:42ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32032000-12-01110.3317/jraas.2000.063The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in manGustav G BelzKerstin Breithaupt-GröglerRaunhild ButzerWinfried FuchsChristian HausdorfChristian MangRationale A quantitative technique was used to compare the pharmacological potency in healthy volunteers of angiotensin II receptor antagonists (AIIA): candesartan cilexetil, losartan, irbesartan, valsartan, and telmisartan. Methods In a randomised, double-blind, parallel-group (4x12 subjects) study, single oral doses of candesartan cilexetil 4, 8 and 16 mg, losartan potassium 25, 50 and 100 mg, valsartan 40, 80 and 160 mg, and irbesartan 75, 150 and 300 mg were administered on three consecutive days. Telmisartan 20, 40 and 80 mg was similarly evaluated in 12 volunteers in an open amendment. Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated. Apparent K i -doses, i.e. doses (in mg) required to induce a two-fold shift in Ang II dose-response curves (equivalent to approx. 50% blockade of receptors) were determined, using Schild regression analysis. Results All treatments dose-dependently attenuated increases in diastolic BP induced by infusion of exogenous Ang II. Candesartan cilexetil appeared to have a more pronounced increase in effect following cumulative dosing. At 24 hours, apparent K i -doses were: candesartan cilexetil 6 mg, irbesartan 123 mg, valsartan 93.5 mg, and telmisartan 54 mg. It was not possible to determine an apparent K i -dose for losartan at 24 hours. Conclusion Consistent with results from experimental pharmacology, candesartan cilexetil displayed the highest pharmacological potency (i.e. antagonistic activity per mg substance) of the AIIAs tested. Apparent K i -doses at 24 hours were within the dose range recommended for clinical use in patients with hypertension.https://doi.org/10.3317/jraas.2000.063 |
| spellingShingle | Gustav G Belz Kerstin Breithaupt-Grögler Raunhild Butzer Winfried Fuchs Christian Hausdorf Christian Mang The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man Journal of the Renin-Angiotensin-Aldosterone System |
| title | The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man |
| title_full | The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man |
| title_fullStr | The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man |
| title_full_unstemmed | The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man |
| title_short | The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man |
| title_sort | pharmacological potency of various at1 antagonists assessed by schild regression technique in man |
| url | https://doi.org/10.3317/jraas.2000.063 |
| work_keys_str_mv | AT gustavgbelz thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT kerstinbreithauptgrogler thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT raunhildbutzer thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT winfriedfuchs thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT christianhausdorf thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT christianmang thepharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT gustavgbelz pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT kerstinbreithauptgrogler pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT raunhildbutzer pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT winfriedfuchs pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT christianhausdorf pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman AT christianmang pharmacologicalpotencyofvariousat1antagonistsassessedbyschildregressiontechniqueinman |